Expansion Therapeutics has raising Series A funding for assistance in combating a variety of genetic disorders, including myotonic dystrophy type 1. This condition, also calls DM1, is the top cause of adult muscular dystrophy. Expansion Therapeutics recently added over $55 million to its current offers in order to help fight this disease. It is believes that symptoms of DM1 show themselves once RNA reaches a toxic level in the body.
Organizations like Sanofi Ventures, as well as 5AM Ventures and Kleiner Perkins all participated in the financing, and RA Capital Management and Alexandria Venture Investments lent their support as well.
RNA are the molecules that turn into proteins and are transferred from our DNA. When RNA is produced in cells and reaches dangerous levels DM1 can occur. The muscles, including the heart, as well as the central nervous and respiratory systems are affected by this disease. Some individuals also experience gastrointestinal distress and hormone imbalance. It is possible for whole families to have DM1 and the condition grows worse with each new generation. At this time, there are no effective treatment for the condition.
Dr. Scott Rocklage and his team are working with Expansion Therapeutics to find a cure for this disease. Dr. Rocklage is also working with a research team to find out more about DM1. There is also a plan in place to advance RNA-targeted molecules. Dr. Rocklage and his team are excited to continue partnering with Expansion Therapeutics and develop medications for patients in need.
Dr. Scott Rocklge is the 5AM Ventures management parter and graduated from the University of California Berkeley. He is also a graduate of the Massachusetts Institute of Technology (MIT), where he earned a Ph.D in Chemistry.
Visit http://5amventures.com/team/scott-m-rocklage-phd/ to learn more.